Why START? Reflections that led to the conduct of this large long-term strategic HIV trial

Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) GV Matthews et al.   HIV MEDICINE

Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) AC Achhra et al.   HIV MEDICINE

Quality of life assessment among HIV-positive persons entering the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) AR Lifson et al.   HIV MEDICINE

Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) MG Law et al.   HIV MEDICINE

Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) EJ Wright et al.   HIV MEDICINE

Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) N Geffen et al.   HIV MEDICINE

Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) KM Kunisaki et al.   HIV MEDICINE

Reported consent processes and demographics: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) E Denning et al.   HIV MEDICINE

Challenges, successes and patterns of enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) J Grarup et al.   HIV MEDICINE

Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) S Sharma et al.   HIV MEDICINE

Transmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) AJ Rodger et al.   HIV MEDICINE

Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) EZ Soliman et al.   HIV MEDICINE

Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) JV Baker et al.   HIV MEDICINE

Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) A Carr et al.   HIV MEDICINE

Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) JD Baxter et al.   HIV MEDICINE

Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease

(2014) Álvaro H. Borges et al.   AIDS

Anti-inflammatory therapies for cardiovascular disease

(2014) P. M. Ridker et al.   EUROPEAN HEART JOURNAL

Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial

(2014) Beatriz Grinsztejn et al.   LANCET INFECTIOUS DISEASES

Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation

(2014) Anna D. Nordell et al.   Journal of the American Heart Association

Rating evidence in treatment guidelines

(2013) Caroline A. Sabin et al.   AIDS

Predicting risk of cancer during HIV infection

(2013) Álvaro H. Borges et al.   AIDS

Risk for Opportunistic Disease and Death after Reinitiating Continuous Antiretroviral Therapy in Patients with HIV Previously Receiving Episodic Therapy

(2013)   ANNALS OF INTERNAL MEDICINE

When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries

(2013)   ANNALS OF INTERNAL MEDICINE

When to start antiretroviral therapy: as soon as possible

(2013) Ricardo A Franco et al.   BMC Medicine

When to start antiretroviral therapy: the need for an evidence base during early HIV infection

(2013) Jens D Lundgren et al.   BMC Medicine

Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study

(2012) Abdel G Babiker et al.   Clinical Trials

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

(2012)   LANCET

Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals

(2012) Daniel A. Duprez et al.   PLoS One

Timing of HAART Initiation and Clinical Outcomes in Human Immunodeficiency Virus Type 1 Seroconverters

(2011) Writing Committee for the CASCADE Collaboration*   ARCHIVES OF INTERNAL MEDICINE

Higher Levels of CRP, D-dimer, IL-6, and Hyaluronic Acid Before Initiation of Antiretroviral Therapy (ART) Are Associated With Increased Risk of AIDS or Death

(2011) David R. Boulware et al.   JOURNAL OF INFECTIOUS DISEASES

Prevention of HIV-1 Infection with Early Antiretroviral Therapy

(2011) Myron S. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health

(2010) James D Neaton et al.   Clinical Trials

Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti

(2010) Patrice Severe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

(2009)   LANCET

Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival

(2009) Mari M. Kitahata et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inferior Clinical Outcome of the CD4+Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+Cell Counts and HIV RNA Levels during Follow‐up

(2008)   JOURNAL OF INFECTIOUS DISEASES

Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study

(2008)   JOURNAL OF INFECTIOUS DISEASES

Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection

(2008) Lewis H Kuller et al.   PLOS MEDICINE